Glycoprotein Analysis for the Diagnostic Evaluation of Platelet Disorders

 

 Buy Article Permissions and Reprints

ABSTRACT

Platelet glycoproteins subserve a wide variety of critical functions in blood platelets. Congenital deficiencies or functional abnormalities in platelet glycoproteins may produce serious bleeding disorders such as Glanzmann thrombasthenia or Bernard-Soulier syndrome. Other hematologic disorders, such as Fanconi anemia and various myelodysplastic syndromes, may also be associated with abnormalities in platelet glycoproteins. Additionally, several acquired disorders involving the major platelet glycoproteins are increasingly being recognized. The large number of techniques, now available to characterize platelet glycoprotein disorders, reflect the many advances in biochemistry, molecular analysis, flow cytometry, and, most recently, proteomics. The application of platelet glycoprotein analysis to a wide range of clinical disorders is reviewed in this article.

REFERENCES

• 1 Nurden A T, Nurden P. Inherited disorders of platelets: an update.  Curr Opin Hematol. 2006;  13 157-162
  PubMedGoogle Scholar
• 2 Coller B S, Shattil S J. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.  Blood. 2008;  112 3011-3025
  CrossrefPubMedGoogle Scholar
• 3 Caen J P, Nurden A T, Jeanneau C et al.. Bernard-Soulier syndrome. A new platelet glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein.  J Lab Clin Med. 1976;  87 586-596
  PubMedGoogle Scholar
• 4 Nurden A T, Caen J P. Specific roles for platelet surface glycoproteins in platelet function.  Nature. 1975;  255 720-722
  CrossrefPubMedGoogle Scholar
• 5 Phillips D R, Agin P P. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins.  J Clin Invest. 1977;  60 535-545
  CrossrefPubMedGoogle Scholar
• 6 Bennett J S, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine.  J Clin Invest. 1979;  64 1393-1401
  CrossrefPubMedGoogle Scholar
• 7 Mustard J F, Packham M A, Kinlough-Rathbone R L, Perry D W, Regoeczi E. Fibrinogen and ADP-induced platelet aggregation.  Blood. 1978;  52 453-466
  PubMedGoogle Scholar
• 8 McGregor J L, Clezardin P, James E, McGregor L, Dechavanne M, Clemetson K J. Identification and characterization of fragments of major glycoproteins from platelet membrane after chymotrypsin treatment.  Eur J Biochem. 1985;  148 97-106
  CrossrefPubMedGoogle Scholar
• 9 Handa M, Titani K, Holland L Z, Roberts J R, Ruggeri Z M. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments.  J Biol Chem. 1986;  261 12579-12585
  PubMedGoogle Scholar
• 10 Ward C M, Andrews R K, Smith A I, Berndt M C. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin.  Biochemistry. 1996;  35 4929-4938
  CrossrefPubMedGoogle Scholar
• 11 Kunicki T J, Nurden A T, Pidard D, Russell N R, Caen J P. Characterization of human platelet glycoprotein antigens giving rise to individual immunoprecipitates in crossed-immunoelectrophoresis.  Blood. 1981;  58 1190-1197
  PubMedGoogle Scholar
• 12 Karpatkin S, Shulman S, Howard L. Crossed immunoelectrophoresis of human platelet membranes.  Methods Enzymol. 1992;  215 440-455
  PubMedGoogle Scholar
• 13 Fabris F, Cordiano I, Mazzuccato M, Pradella P, Randi M LG. Labeling of platelet surface glycoproteins with biotin derivatives.  Thromb Res. 1992;  66 409-419
  CrossrefPubMedGoogle Scholar
• 14 Gibbins J M. Techniques for analysis of proteins by SDS-polyacrylamide gel electrophoresis and Western blotting.  Methods Mol Biol. 2004;  273 139-152
  PubMedGoogle Scholar
• 15 Michelson A D. Evaluation of platelet function by flow cytometry.  Pathophysiol Haemost Thromb. 2006;  35 67-82
  CrossrefPubMedGoogle Scholar
• 16 Michelson A D, Linden M D, Barnard M R, Furman M I, Frelinger III A L. Flow cytometry. In: Michelson AD Platelets. 2nd ed. New York, NY; Elsevier 2007: 545-564
  Google Scholar
• 17 Rand M L, Leung R, Packham M A. Platelet function assays.  Transfus Apher Sci. 2003;  28 307-317
  PubMedGoogle Scholar
• 18 Enjeti A K, Lincz L F, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology.  Semin Thromb Hemost. 2007;  33 771-779
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Israels S. Diagnostic evaluation of platelet function disorders in neonates and children: an update.  Semin Thromb Hemost. 2009;  35 181-188
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Althaus K, Greinacher A. MYH9-related platelet disorders.  Semin Thromb Hemost. 2009;  35 189-203
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function.  Semin Thromb Hemost. 2009;  35 158-167
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 McGlasson D, Fritsma G. Whole blood platelet aggregometry and platelet function testing.  Semin Thromb Hemost. 2009;  35 168-180
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Nurden A, Fiore M, Pillois X, Nurden P. Genetic testing in the diagnostic evaluation of inherited platelet disorders.  Semin Thromb Hemost. 2009;  35 204-212
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 Weiss H. Impaired platelet procoagulant mechanisms in patients with bleeding disorders.  Semin Thromb Hemost. 2009;  35 233-241
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Glanzmann Thombasthenia Database .Mount Sinai School of Medicine, Department of Medicine. 2008 Available at: http://www.sinaicentral.mssm.edu/intranet/research/glanzmann Accessed January 28, 2009
  Google Scholar
• 26 Kiyoi T, Tomiyama Y, Honda S et al.. A naturally occurring Tyr143His alpha IIb mutation abolishes alpha IIb beta 3 function for soluble ligands but retains its ability for mediating cell adhesion and clot retraction: comparison with other mutations causing ligand-binding defects.  Blood. 2003;  101 3485-3491
  CrossrefPubMedGoogle Scholar
• 27 Goodall A H, Appleby J. Flow-cytometric analysis of platelet-membrane glycoprotein expression and platelet activation.  Methods Mol Biol. 2004;  272 225-253
  PubMedGoogle Scholar
• 28 Shattil S J, Cunningham M, Hoxie J A. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry.  Blood. 1987;  70 307-315
  CrossrefPubMedGoogle Scholar
• 29 Lanza F, Stierle A, Fournier D et al.. A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg–214Trp mutation.  J Clin Invest. 1992;  89 1995-2004
  CrossrefPubMedGoogle Scholar
• 30 Bierling P, Fromont P, Elbez A, Duedari N, Kieffer N. Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient.  Vox Sang. 1988;  55 109-113
  CrossrefPubMedGoogle Scholar
• 31 Male C, Koren D, Eichelberger B, Kaufmann K, Panzer S. Monitoring survival and function of transfused platelets in Glanzmann thrombasthenia by flow cytometry and thrombelastography.  Vox Sang. 2006;  91 174-177
  CrossrefPubMedGoogle Scholar
• 32 Giannini S, Mezzasoma A M, Guglielmini G, Rossi R, Falcinelli E, Gresele P. A new case of acquired Glanzmann's thrombasthenia: diagnostic value of flow cytometry.  Cytometry B Clin Cytom. 2008;  74 194-199
  PubMedGoogle Scholar
• 33 Vijapurkar M, Ghosh K, Shetty S, McLane M A, Moura da Silva A M, Butera D. A simple, novel and robust test to diagnose type I Glanzmann thrombasthenia.  Haematologica. 2008;  93 797-798
  CrossrefPubMedGoogle Scholar
• 34 Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome.  Blood. 2002;  100 2102-2107
  CrossrefPubMedGoogle Scholar
• 35 Miller J L, Lyle V A, Cunningham D. Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ib alpha leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease.  Blood. 1992;  79 439-446
  PubMedGoogle Scholar
• 36 Vettore S, Scandellari R, Moro S et al.. Novel point mutation in a leucine-rich repeat of the GPIbalpha chain of the platelet von Willebrand factor receptor, GPIb/IX/V, resulting in an inherited dominant form of Bernard-Soulier syndrome affecting two unrelated families: the N41H variant.  Haematologica. 2008;  93 1743-1747
  CrossrefPubMedGoogle Scholar
• 37 Giannini S, Mezzasoma A M, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.  Haematologica. 2007;  92 1647-1654
  CrossrefPubMedGoogle Scholar
• 38 Kunicki T J, Johnson M M, Aster R H. Absence of the platelet receptor for drug-dependent antibodies in the Bernard-Soulier syndrome.  J Clin Invest. 1978;  62 716-719
  CrossrefPubMedGoogle Scholar
• 39 Visentin G P, Wolfmeyer K, Newman P J, Aster R H. Detection of drug-dependent, platelet-reactive antibodies by antigen-capture ELISA and flow cytometry.  Transfusion. 1990;  30 694-700
  CrossrefPubMedGoogle Scholar
• 40 van den Bemt P M, Meyboom R H, Egberts A C. Drug-induced immune thrombocytopenia.  Drug Saf. 2004;  27 1243-1252
  CrossrefPubMedGoogle Scholar
• 41 Nurden A T, Nurden P, Bermejo E, Combrie R, McVicar D W, Washington A V. Phenotypic heterogeneity in the gray platelet syndrome extends to the expression of TREM family member, TLT-1.  Thromb Haemost. 2008;  100 45-51
  PubMedGoogle Scholar
• 42 Drouin A, Favier R, Masse J M et al.. Newly recognized cellular abnormalities in the gray platelet syndrome.  Blood. 2001;  98 1382-1391
  CrossrefPubMedGoogle Scholar
• 43 Diamandis M, Paterson A D, Rommens J M et al.. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes.  Blood. 2008;  , November 6 (Epub ahead of print)
  PubMedGoogle Scholar
• 44 Diamandis M, Veljkovic D K, Maurer-Spurej E, Rivard G E, Hayward C P. Quebec platelet disorder: features, pathogenesis and treatment.  Blood Coagul Fibrinolysis. 2008;  19 109-119
  CrossrefPubMedGoogle Scholar
• 45 Noris P, Guidetti G F, Conti V et al.. Autosomal dominant thrombocytopenias with reduced expression of glycoprotein Ia.  Thromb Haemost. 2006;  95 483-489
  PubMedGoogle Scholar
• 46 Arthur J F, Dunkley S, Andrews R K. Platelet glycoprotein VI-related clinical defects.  Br J Haematol. 2007;  139 363-372
  PubMedGoogle Scholar
• 47 Dunkley S, Arthur J F, Evans S, Gardiner E E, Shen Y, Andrews R K. A familial platelet function disorder associated with abnormal signalling through the glycoprotein VI pathway.  Br J Haematol. 2007;  137 569-577
  CrossrefPubMedGoogle Scholar
• 48 Holzhauer S, Sitaru A G, Ebell W et al.. Decreased platelet reactivity identified by whole blood flow cytometry in Fanconi anaemia patients.  Thromb Haemost. 2007;  98 1291-1297
  PubMedGoogle Scholar
• 49 Swerdlow S H, Campo E, Harris N L et al.. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France; International Agency for Research on Cancer 2008
  Google Scholar
• 50 Seidl C, Siehl J, Ganser A et al.. Platelet glycoprotein expression in patients with myelodysplastic syndrome.  Thromb Res. 2000;  100 27-34
  CrossrefPubMedGoogle Scholar
• 51 Izumi M, Takeshita A, Shinjo K et al.. Decreased amount of mpl and reduced expression of glycoprotein IIb/IIIa and glycoprotein Ib on platelets from patients with refractory anemia: analysis by a non-isotopic quantitative ligand binding assay and immunofluorescence.  Eur J Haematol. 2001;  66 245-252
  CrossrefPubMedGoogle Scholar
• 52 Senzel L, Gnatenko D V, Bahou W F. Genomic and proteomic applications in diagnosis of platelet disorders and classification.  Semin Thromb Hemost. 2008;  34 532-538
  Article in Thieme ConnectPubMedGoogle Scholar
• 53 Curtis B R. Genotyping for human platelet alloantigen polymorphisms: applications in the diagnosis of alloimmune platelet disorders.  Semin Thromb Hemost. 2008;  34 539-548
  Article in Thieme ConnectPubMedGoogle Scholar
• 54 Garcia B A, Smalley D M, Cho H, Shabanowitz J, Ley K, Hunt D F. The platelet microparticle proteome.  J Proteome Res. 2005;  4 1516-1521
  CrossrefPubMedGoogle Scholar
• 55 Maynard D M, Heijnen H F, Horne M K, White J G, Gahl W A. Proteomic analysis of platelet alpha-granules using mass spectrometry.  J Thromb Haemost. 2007;  5 1945-1955
  CrossrefPubMedGoogle Scholar
• 56 Maurer-Spurej E, Kahr W H, Carter C J, Pittendreigh C, Cameron M, Cyr T D. The value of proteomics for the diagnosis of a platelet-related bleeding disorder.  Platelets. 2008;  19 342-351
  CrossrefPubMedGoogle Scholar

Jonathan L MillerM.D. Ph.D. 

Director of Medical Center Laboratories, Professor and Vice Chairman, Department of Pathology

The University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637

Email: jlmiller@bsd.uchicago.edu